Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

350 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.
Sunami K, Shinagawa K, Sawamura M, Sakai A, Saburi Y, Imamura Y, Mizuno I, Tamaki S, Kamimura T, Tsuda H, Gondo H, Hino N, Shimazaki C, Miyata A, Tajima F, Takemoto Y, Miwa A, Chou T, Harada M. Sunami K, et al. Among authors: shimazaki c. Int J Hematol. 2009 Dec;90(5):635-642. doi: 10.1007/s12185-009-0445-8. Epub 2009 Nov 21. Int J Hematol. 2009. PMID: 19936876 Clinical Trial.
A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma.
Fuchida SI, Sunami K, Matsumoto M, Okumura H, Murayama T, Miyamoto T, Otsuka E, Fujishima N, Izumi T, Tamaki S, Hiramatsu Y, Kuroda Y, Shimazaki C, Akashi K, Harada M; Japan Study Group for Cell Therapy and Transplantation (JSCT). Fuchida SI, et al. Among authors: shimazaki c. Int J Hematol. 2019 Jan;109(1):107-114. doi: 10.1007/s12185-018-2543-y. Epub 2018 Oct 4. Int J Hematol. 2019. PMID: 30284685 Clinical Trial.
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma.
Murakami H, Fujii H, Inaba T, Shimazaki C, Okamoto S, Miwa A, Sawamura M, Abe M, Chou T, Asaoku H, Kitahara Y, Hayashi K, Kosaka M, Togawa A, Takatsuki K; Japan Myeloma Study Group. Murakami H, et al. Among authors: shimazaki c. Eur J Haematol. 2004 Sep;73(3):169-73. doi: 10.1111/j.1600-0609.2004.00282.x. Eur J Haematol. 2004. PMID: 15287913 Clinical Trial.
Phase II clinical study of cladribine in the treatment of hairy cell leukemia.
Machii T, Chou T, Suzuki M, Ohe Y, Katagiri S, Kitano EK, Kitano K, Fujiyama Y, Izumi T, Shimazaki C, Nanba K, Ohashi Y, Kitani T; Cladribine Study Group. Machii T, et al. Among authors: shimazaki c. Int J Hematol. 2005 Oct;82(3):230-5. doi: 10.1532/IJH97.04128. Int J Hematol. 2005. PMID: 16207596 Clinical Trial.
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Murakami H, et al. Among authors: shimazaki c. Eur J Haematol. 2007 Sep;79(3):234-9. doi: 10.1111/j.1600-0609.2007.00908.x. Epub 2007 Jul 26. Eur J Haematol. 2007. PMID: 17655699 Clinical Trial.
A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Kodama T, Abe M, Iida S, Ozaki S, Sakai A, Sawamura M, Shimazaki C, Miyata A, Wakayama T, Murakami H. Kodama T, et al. Among authors: shimazaki c. Clin Lymphoma Myeloma. 2009 Apr;9(2):154-9. doi: 10.3816/CLM.2009.n.037. Clin Lymphoma Myeloma. 2009. PMID: 19406727
350 results